Summary We report the immunomodulatory effects of an intravenous treatment with FAab')2 fragments of the bispecific monoclonal antibody BIS-l during subcutaneous recombinant interleukin 2 (rIL-2) therapy of renal cell cancer (RCC) patients. BIS-1 is directed against both the CD3 antigen on T cells and the EGP-2 molecule on carcinoma cells and some normal epithelia. The amount of BIS-l F(ab'), bound to peripheral blood lymphocytes (PBLs) increased dose-dependently. This occupation degree was highest at the end of the 2 h infusion and rapidly decreased subsequently. During the first hour of BIS-1 F(ab')2 infusion the number of PBLs decreased slowly. This was followed by an increase in serum tumour necrosis factor alpha ([NF-a) concentrations and a rapid decrease in the numbers of peripheral blood lymphocytes. monocytes and eosinophils. In our view, the most likely explanation for the observed decrease in occupation degree of BIS-1 F(ab')2 and the rise in TNF-a levels is based on the assumption that BIS-1-carrying T cells leave the circulation. The CD3 antigens on these extravasated T cells become cross-linked by EGP-2 antigens, inducing TNF-a secretion. This results in an enhanced decrease in the numbers of PBLs. monocytes and eosinophils. These preliminary results suggest that BIS-1 F(ab'), treatment during IL-2 therapy may induce local T-cell activation.
T cells appear to play a key role in interleukin 2 (IL-2)-induced remissions of immunogenic cancers (Janssen et al., 1994a) . Therefore, improvements of immunotherapy might be obtained from enhancing T-cell activation, increasing Tcell migration to tumour sites. and/or reinforcing tumour-cell recognition by T cells.
IL-2 therapy induces some T-cell activation (Thompson et al., 1989; Yoshino et al.. 1991) , although this was found to last for only 1-2 weeks (Janssen et al., 1993) . In an attempt to improve tumour-directed T-cell activation we have added to a standard subcutaneous, recombinant (s.c.) (r) IL-2 treatment an intravenous (i.v.) administration of bispecific monoclonal antibody BIS-1. BIS-1 is directed against both the CD3 antigen on T cells [derived from the monoclonal antibody (MAb) RIV-9] and the EGP-2 molecule (derived from the MAb MOC-31; De Leij et al., 1994) on carcinoma cells. EGP-2 is a 38 kDa membrane protein which is abundantly present on a large array of normal and malignant epithelia. The rationale for combining rIL-2 with BIS-1 is that, in addition to the stimulation of T cells by rIL-2, BIS-1 might guide specific T-cell recognition of tumour cells by cross-linking the CD3 antigens to EGP-2.
Previously we published the clinical results of the i.v. application of BIS-1 F(ab'). in RCC patients undergoing rIL-2 therapy (Kroesen et al., 1994) . In the present report we describe the properties of the antibody in vivo and the immunomodulatory effects induced by this antibody. The present results provide insight into the previously observed toxicity and immunomodulatory aspects accompanying i.v. administration of BIS-l F(ab')2. These results support our postulated theory that BIS-1 F(ab')2 loaded T cells leave the circulation and become activated at EGP-2-positive sites.
Materials and metbods
Patients Fourteen patients were entered in this study. Patients received s.c. rIL-2 therapy as described earlier (Sleijfer et at., 1992) . In short, they received a 5 day cycle of Cetus rIL-2 (EuroCetus, Amsterdam, The Netherlands) every week for 4 consecutive weeks. During the first 5 day cycle, 18 x 0O6 IU rIL-2 were given once daily. In the following cycles the dose in the first 2 days was reduced to 9 x 106 units. Patients were treated with BIS-1 F(ab')2 at doses of tLg kg-' (n = 4), or 3 Lg kg-' (n = 4), or 5 Lg kg-(n = 6), administered as a 2 h i.v. infusion. Each patient received two courses of BIS-1 during s.c. rIL-2 therapy. The first treatment was on the first day of the second treatment week of IL-2 therapy, and the second course was on the first or second day of the third week of IL-2 therapy (Kroesen et al.. 1994) . Since no differences between first and second courses were observed concerning toxicity or immunomodulatory effects, the results of both courses are combined in the present report.
Flow cvtometric analysis of the amount of BIS-J F(ab')2 bound to T cells EDTA-treated blood collected from the patients was immediately placed on ice and all further experiments were carried out at 0°C unless otherwise stated. To 100 ,Ll samples of whole blood 4 IL of saturating BIS-1 F(ab')2 (200 ng) determined.
degree of BIS-1 F(ab')2 immediately at the end of the 2 h infusion (T= 2 h) increased dose dependently (Table I, column 3) . Subsequent analysis at various time points after ending the infusion, showed that the occupation degree of BIS-1 F(ab'), decreased quickly in time at all treatment concentrations (Table I , in vivo data).
To study the possibility that the i.v. BIS-1 F(ab')2 treatment had induced down-modulation of CD3 antigens itself on peripheral blood T cells, the MFI of the various samples taken in time incubated with saturating BIS-1 F(ab')2 at 0'C (to prevent modulation during staining) for 30 min was measured. MFl values of samples taken at T= 2 h, T= 3 h and T = 5 h were comparable to pretreatment values (not shown), indicating that no significant modulation of the CD3 antigen itself had occurred in vivo.
Immediately after ending the infusion (T = 2 h), non-cellbound BIS-1 F(ab')2 fragments were present in plasma of patients treated with 3 or 5 gg kg-(plasma samples of patients treated with 1 gig kg-' were not analysed increase in MFl from T = 0 h to T = 2 h. varying from 2 to 16%. was observed.
In vitro modulation of BIS-1 F(ab')2 The decrease in time of BIS-1 F(ab')2 occupation in vivio could be due to the fact that only CD3 molecules with bound BIS-1 F(ab')2 become modulated. We have studied such a possibility by performing in vitro experiments.
Firstly, whole blood samples from BIS-1 F(ab')2-treated patients (3 or 5ptgkg-') taken at T=2h (end of infusion)
were further incubated in vitro at 3TC for 1 and 3 h, before staining and fixing, mimicking the in i'ivo situation. In patients treated with 5 jig kg-' the occupation degree increased during the first hour of in vitro incubation (T= 2 h + I h) after which the occupation degree decreased again (T = 2 h + 3 h). However, this decrease was not as pronounced as in vivo (Table I, '98 degree during in vitro incubation decreased continuously, but not as much as the in vivo decrease.
Secondly. to study BIS-1 F(ab')2 modulation in more detail, the effect of vanrous concentrations of BIS-1 F(ab')2 on whole blood samples of healthy donors was tested. Figure  1 shows that there is only moderate modulation (<20%) at low concentrations (<100 ng ml') of antibody, whereas high concentrations (>100 ng ml-') induced modulation up to 80%. Modulation was higher when the antibody was not washed away.
BIS-J F(ab'}. treatment induces lymphopenia
BIS-1 F(ab')2 administration at 3 and Sligkg-', but not at 1 ;Lg kg-'. induced leucopenia. Leucopemia was moderate at 3 tig kg-' but profound effects were seen at 5 Lg kg-'. After 24 h. leucocyte numbers had almost, but not completely., returned to their pretherapy values (not shown). Changes in leucocyte numbers during the 2 h infusion are given in detail in Figure 2 . In patients treated with 5 ytg kg-' BIS-l F(ab')2, the number of lymphocytes decreased slowly but immediately from T= O h to T= 1.5 h, followed by a more rapid decrease until T= 3 h. The number of monocytes stayed stable or increased during the first hour followed by a rapid disappearance of virtually all monocytes within the following hour. The number of eosinophils followed a pattern comparable to that of the lymphocytes. In contrast to the strong decrease of these cell types, the number of neutrophils decreased only moderately during the last half hour of infusion, after which the amount increased again, exceeding preinfusion levels.
BIS-I FR ab'v treatment induces T.VF-a production
Levels of plasma TNF-a were determined in two patients before and during the infusion of 5 tg kg-' BIS-l F(ab')2 at half hour time intervals. Figure 3 shows that BIS-1 F(ab')2 treatment induced an increase in TNF-a levels between T= I h and T= 1.5 h. TNF-a reached peak levels at T= 2 h after which the levels of TNF-x decreased rapidly again (as demonstrated in one patient).
BIS-J F(ab') treatment induces lymphocyte proliferation only in the presence of To study the specificity of BIS-1 F(ab')2 and how BIS-1 F(ab')2 may affect lymphocyte activation during IL-2 therapy, whole blood samples taken from RCC patients receiving IL-2 therapy were incubated with BIS-1 F(ab')2 in the presence of EGP-2-positive or EGP-2-negative tumour cells. Figure 4 shows that BIS-1 F(ab') induces lymphocyte proliferation only in the presence of EGP-2-positive tumour cells. Using BIS-1 IgG instead of BIS-1 F(ab')2 resulted in higher proliferation rates in all cases.
Discussion
This study describes the properties of intravenously administered BIS-1 in terms of its binding capacity to lymphocytes and of its effects on leucocyte and lymphocyte subpopulations. In an earlier study we found the unexpected result that BIS-1 treatment of RCC patients induces lymphopenia and TNF-x production (Kroesen et al.. 1994 ). The present study of the behaviour of the BIS-1 F(ab')2 antibody and the more detailed study of the immunomodulatory effects dunrng infusion of the antibody may explain this surprising phenomenon, as will be discussed here.
After ending the i.v. infusion of BIS-1 F(ab')2 the amount of cell bound to BIS-1 F(ab')2 appears to decrease quickly in time. There are two conceivable explanations for this phenomenon. Firstly, CD3 molecules which have bound BIS-1 F(ab') could become internalised. Secondly, T cells which have bound BIS-1 F(ab')2 leave the circulation causing a decrease in the observed MFI of BIS-1 F(ab')2 expression on T cells. Both possibilities will be discussed here. It has been reported that in vitro CD3 MAbs become down modulated from the T-cell surface due to internalisation of the CD3 molecule/CD3 MAb complex (Boyer et al.. 1991) . The rate and degree of internalisation of monovalent Fab-fragments of OKT3 in those studies appeared to be lower than those of intact Ig. Figure 1 shows that BIS-1 F(ab'), fragments, containing one Ag binding site of the CD3 MAb RIV-9, also induce modulation in vitro, at least at high concentrations. The modulation of BIS-1 F(ab')2 was higher when free antibodies were not washed away after in vitro incubation of cells with BIS-l F(ab')2 (Figure 1 ). This resembles earlier findings with whole Ig CD3 MAb (van Oosterhout et al., 1992 ngm1-1 induce significant modulation (Figure 1 ).
Thirdly, the MFI of CD3-immunostained T cells, reflecting the total number of CD3 antigens present on the T-cell surface, did not change during treatment. These results suggest that the decrease in bound BIS-1 is not due to modulation only. Another possible explanation for the decreased detection of bound BIS-1 is that BIS-1 occupied T cells leave the peripheral blood compartment resulting in the virtual decrease in PBL-bound BIS-1. This is supported by the observed transitory reduction in leucocyte counts during and after the BIS-1 infusion.
The production of TNF-a is rather surprising, since TNF-a production by T cells is only induced by crosslinking of CD3 antigens (Woodle et al.. 1991 In summary. these results form the first evidence that BIS-1 F(ab').-loaded T cells leave the circulation and become locally activated by cross-linking of their CD3 antigens via EGP-2. This results in a local but subsequently also systemic inflammatory reaction. which might be supportive for immune cell-mediated tumour regression.
